Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 435 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Excretion Clear all
Completed Not applicable Interventional

This Study Will Collect Clinical and Patient Reported Satisfaction Data From Males Requiring Urine Output Management Overnight in the Home Setting.

NCT06850259
View directory record Official record
Conditions
Urinary Incontinence
Interventions
PureWick™ System, UltraFlex™ Self-Adhering Male External Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
65 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Greenacres City, Florida • Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 3, 2026, 4:10 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body

NCT00800280
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
PD 0332334, cimetidine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 16, 2010 · Synced Sep 3, 2026, 4:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Perinatal Anal Incontinence Through Early Pelvic Floor Muscle Training: a Prospective Pilot Study

NCT02270008
View directory record Official record
Conditions
Perinatal and Postpartum Anal Incontinence
Interventions
Pelvic floor training
Other
Lead sponsor
Emory University
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 3, 2026, 4:10 AM EDT
Terminated Not applicable Interventional Results available

Comparison of the Efficacy of a Biological Implant to Reinforce Overlapping Sphincter Repair Versus Overlapping Sphincter Repair Alone

NCT01044589
View directory record Official record
Conditions
Fecal Incontinence, Anal Incontinence
Interventions
Biodesign Tissue Repair Graft, Overlapping Sphincter Repair
Device · Other
Lead sponsor
Massarat Zutshi
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 3, 2026, 4:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Food Matrix Effect on Flavanol Absorption, Metabolism and Excretion: Methylxanthines

NCT03526107
View directory record Official record
Conditions
Healthy
Interventions
CF Control, CF-Theobromine, CF-Caffeine
Other
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 60 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 3, 2026, 4:10 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Randomized Study Of Novel Enuresis Alarm vs Standard Bedwetting Alarm

NCT05214131
View directory record Official record
Conditions
Bedwetting, Nocturnal Enuresis, Urinary Incontinence
Interventions
gogoband, SNEA group
Device
Lead sponsor
Yale University
Other
Eligibility
6 Years to 21 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 3, 2026, 4:10 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction

NCT03837470
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
0.9% Sodium Chloride, Furosemide 40 mg
Drug
Lead sponsor
Adhish Agarwal
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 3, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mass Balance Study of KBP-5074 in Healthy Male Subjects

NCT04634812
View directory record Official record
Conditions
Healthy
Interventions
KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 3, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500

NCT06738836
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[14C]-EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 3, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose

NCT07102095
View directory record Official record
Conditions
Hepatic Insufficiency, Liver Diseases, Pharmacokinetics, Drug Metabolism
Interventions
Sevabertinib
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 3, 2026, 4:10 AM EDT
Suspended Phase 1Phase 2 Interventional

Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical

NCT06643494
View directory record Official record
Conditions
Prostate Cancer
Interventions
N-111, Placebo
Dietary Supplement · Other
Lead sponsor
Optimal Health Research
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 3, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

NCT02274181
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
19 Years to 60 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Sep 3, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects

NCT04415645
View directory record Official record
Conditions
Healthy Adult Male
Interventions
[14C]-VVZ-149
Drug
Lead sponsor
Vivozon, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 3, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of [3H] BMS747158 in Healthy Male Subjects

NCT00930631
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
[3H] BMS747158
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 3, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

NCT04234672
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-831 Oral Tablet, [14C]TAK-831 IV Infusion, [14C]TAK-831 Oral Suspension
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 3, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects

NCT01503866
View directory record Official record
Conditions
Healthy
Interventions
bardoxolone methyl
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 3, 2026, 4:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Kava on the Body's Elimination of Caffeine and Dextromethorphan

NCT00009542
View directory record Official record
Conditions
Healthy
Interventions
kava (Piper methysticum)
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 4:10 AM EDT
Withdrawn Phase 4 Interventional

Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)

NCT04235049
View directory record Official record
Conditions
HCV Infection
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 3, 2026, 4:10 AM EDT
Active, not recruiting Phase 1 Interventional

Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

NCT02637934
View directory record Official record
Conditions
Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Interventions
[18F]FluorThanatrace, PET/CT imaging sessions
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 3, 2026, 4:10 AM EDT
Terminated Phase 1 Interventional Results available

Targeted Investigation of Microbiome Elimination

NCT05177328
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
S. hominis A 9 Product, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 3, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants

NCT05630287
View directory record Official record
Conditions
Healthy
Interventions
[14C]-Selpercatinib, Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Sep 3, 2026, 4:10 AM EDT
Recruiting No phase listed Observational

Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study

NCT07301216
View directory record Official record
Conditions
Wilson Disease
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 3, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects

NCT04241393
View directory record Official record
Conditions
Healthy Subjects
Interventions
Tavapadon tablet, Tavapadon [14C] suspension
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Sep 3, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Radiolabeled Study of CC-122 in Healthy Subjects

NCT02234999
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-122
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Sep 3, 2026, 4:10 AM EDT